Back to results
US 2022/0024963 A1Published application
Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds
AssigneeNuCana plc
InventorsHugh Griffith, Michaela Serpi, Fabrizio Pertusati, Magdalena Slusarczyk, Samuele Di Ciano
Life of this patent
Estimating the term…
Abstract
The present invention provides to salts of triphosphate phosphoramidates which are useful in the treatment of cancer.
Claims20
A compound of formula (I), or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is independently at each occurrence selected from:
- C1-C24-alkyl, C3-C24-alkenyl, C3-C24-alkynyl, C0-C4-alkylene-C3-C8-cycloalkyl and C0-C4-alkylene-aryl;
- R2 and R3 are each independently at each occurrence selected from H, C1-C6-alkyl and C1-C3-alkylene-R7;
- or R2 and R3 together with the atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl group;
- R4 is independently at each occurrence H or C1-C4-alkyl;
- or R4, a group selected from R2 and R3 and the atoms to which they are attached may form a 3- to 6-membered heterocycloalkyl group;
- R5 is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8-cycloalkyl, 3- to 7-membered heterocycloalkyl, C1-C3-alkylene-R5a and C1-C8-alkyl, said aryl being optionally fused to C6-C8-cycloalkyl;
- R5a is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C3-C8-cycloalkyl, 3- to 7-membered heterocycloalkyl, said aryl being optionally fused to C6-C8-cycloalkyl;
- R6 is independently selected from:
- R7 is independently at each occurrence selected from aryl, imidazole, indole, SRa, ORa, CO2Ra, CO2NRaRa, NRaRb and NH(═NH)NH2;
- R8 is independently selected from H and
- Z1 and Z2 are each independently selected from O and S;
- R9 is independently selected from H and Me;
- Y is independently selected from H, F, Cl and OMe;
- X is at each occurrence selected from H and a pharmaceutically acceptable cation;
- provided that in at least one occurrence X is a pharmaceutically acceptable cation;
- wherein any aryl group is either phenyl or naphthyl;
- wherein where any of R1, R2, R3, R4, R5 or R7 is an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, that alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally substituted with from 1 to 4 substituents selected from:
- halo, nitro, cyano, NRaRa, NRaS(O)2Ra, NRaC(O)Ra, NRaCONRaRa, NRaCO2Ra, ORa;
- SRa, SORa, SO3Ra, SO2Ra, SO2NRaRa, CO2Ra C(O)Ra, CONRaRa, CRaRaNRaRa, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-haloalkyl;
- wherein Ra is independently at each occurrence selected from:
- H and C1-C4-alkyl;
- and Rb is independently at each occurrence selected from:
- H, and C1-C4-alkyl and C(O)—C1-C4-alkyl.
22 more elements
Dependencies are inferred from the claim text.